Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia

European Journal of Internal Medicine
José Delgado AlvesD Isenberg

Abstract

Background: Splenectomy has been performed to treat refractory autoimmune thrombocytopenia. However, some reports have suggested that an increased risk of thrombosis could be present in splenectomized patients. This study aims to evaluate the possibility of an increased risk of thrombosis after splenectomy in patients with systemic lupus and antiphospholipid syndrome. Methods: Thrombotic-related events in patients with systemic lupus erythematosus (SLE) and/or primary antiphospholipid syndrome (PAPS), before and after splenectomy for severe thrombocytopenia, were compared. Clinical data, laboratory investigations, and anticoagulation or antiaggregation treatment data were collected from the notes of outpatients attending three European centers. Results: Twenty patients who had had a splenectomy were identified: eight with SLE, five with PAPS, and seven with SLE and APS. The mean time between diagnosis and splenectomy was 3.1 years and mean follow-up was 6.5 years. There were no differences in anticardiolipin antibody titers, lupus anticoagulant, anti-DNA or anti-nuclear antibodies before and after surgery. The incidence of venous events before and after splenectomy was not significantly different. There was a trend towards an i...Continue Reading

References

Jul 1, 1978·Archives of Surgery·M A BoxerL Ellman
Mar 1, 1985·Annals of Internal Medicine·S HallC H McKenna
Feb 1, 1985·British Journal of Haematology·E N HarrisG R Hughes
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Jan 1, 1960·Annals of Internal Medicine·Y RABINOWITZ, W DAMESHEK

❮ Previous
Next ❯

Citations

Sep 10, 2014·Thrombosis Research·J GebhartK Geissler
May 24, 2011·Autoimmunity Reviews·Ana CamparCarlos Vasconcelos
Oct 24, 2015·International Journal of Surgery·Debora H LeeEric J Ley
Mar 31, 2009·Seminars in Hematology·James B Bussel
Apr 18, 2008·Blood Reviews·Imad UthmanMunther Khamashta
Apr 10, 2015·Current Rheumatology Reports·Renata Ferreira RosaDanieli Andrade
Mar 6, 2015·Current Rheumatology Reports·Bahar Artim-EsenMurat İnanç
Jan 4, 2018·Blood·Shruti ChaturvediKeith R McCrae
Dec 17, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Susanna TanChin Lee

❮ Previous
Next ❯

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.